Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_assertion type Assertion NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_head.
- NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_assertion description "[Starting from sorafenib and sunitinib, several targeted therapies have been approved for mRCC treatment, with a long list of agents in course of evaluation, such as tivozanib, cediranib, and VEGF-Trap.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_provenance.
- NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_assertion evidence source_evidence_literature NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_provenance.
- NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_assertion SIO_000772 24093097 NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_provenance.
- NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_assertion wasDerivedFrom befree-2016 NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_provenance.
- NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_assertion wasGeneratedBy ECO_0000203 NP1116133.RAiHBc5GAXPJ1ddKv7wgzAcNZADRvk-VkA-z7TbdUFbWE130_provenance.